14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score -1.431 18 days ( -13.33 % )
Last Price $0.0850 10.39 %
High/ Low $0.0751 - $0.0850 5.33%
Chg 7 Days 4.94 % $0.0810 $0.0850
Chg 30 Days 11.40 % $0.0763 $0.0850
Chg 12 mos -90.64 % $0.91 $0.0850
Trend - 3 mos -67.81 % Width: 463.75 %
Trend - 12 mos -95.20 % Width: 114.75 %
Pred. range - 3 mos N/A - $0.0422 -100.00 % - -50.30 %
Pred. range - 12 mos N/A - $0.0027 -100.00 % - -96.85 %
Short MA avg 3 mos Buy Apr 19, 2024 - 2 days
Long MA avg 3 mos Sell Feb 27, 2024 - 39 days
Short/Long MA avg 3 mos Sell Mar 01, 2024 - 36 days
Short MA avg 12 mos Buy Apr 19, 2024 - 2 days
Long MA avg 12 mos Sell Mar 05, 2024 - 34 days
Short/Long MA avg 12 mos Sell Mar 19, 2024 - 24 days
Pivot Short Buy Mar 20, 2024 - 23 days
Bollinger Buy Apr 22, 2024 - 1 day
MACD Buy No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About Atreca Inc.

Atreca. Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, ... BCEL Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT